Articles related to CLINICAL TRIALS

The recent study on vemurafenib and obinutuzumab offers a promising treatment pathway for previously untreated HCL patients, achieving high rates of complete remission and minimal residual disease negativity.

The recent phase 3 trial on 177Lu-PSMA-617 offers compelling evidence for its efficacy in extending survival rates for advanced prostate cancer patients. Could this therapy eventually become an addition to your treatment arsenal?

New pharmaceutical interventions are significantly broadening the scope of presbyopia treatment. Discover how these emerging options can enhance your practice and improve patient care.

Recent findings from the MARS 2 trial challenge traditional treatment protocols for mesothelioma, indicating that chemotherapy alone may offer improved outcomes over combined surgical approaches. Discover why experts are re-evaluating long-standing surgical treatments.

The phase 2 trial provides evidence that dabrafenib combined with trametinib could serve as a more effective and safer first-line treatment option for pediatric low-grade gliomas with BRAF V600 mutations. Evaluate the data to consider how this may influence your treatment protocols.

Discover how MatchMiner is transforming the landscape of precision medicine by efficiently connecting patients with suitable clinical trials, thereby accelerating the adoption of personalized therapies.